This website provides general educational information and does not replace professional medical advice, diagnosis, or treatment. Medical guidance and research findings may change. Consult qualified healthcare professionals for individual health concerns.
What Is a Clinical Trial?
A clinical trial is a research study in which people volunteer to receive an intervention—such as a vaccine, medicine, device or behavioral program—so that researchers can evaluate its safety and effects. Clinical trials follow a written plan called a protocol, which specifies who can take part, what will be done, how outcomes will be measured and how participants will be protected.
The primary purpose of a clinical trial is to produce generalizable knowledge. An investigational product is, by definition, not yet proven. Some participants may benefit, some may not, and some may experience side effects. Established medical treatment, by contrast, is care already shown to be effective and recommended in clinical guidelines.
Why Clinical Trials Are Conducted
Laboratory and animal research can suggest that an intervention might work, but only studies in people can show whether it is safe and effective for human use. Clinical trials answer questions such as: Does this vaccine reduce infection? What dose works best? Is a new approach better than the current standard? Are there side effects that occur only rarely? Without well-designed trials, health decisions would rely on guesswork, anecdote or tradition.
Understanding Clinical Research Phases
- Phase 1
Usually involves a small number of participants, often healthy volunteers for vaccines. The focus is safety, tolerability, dosing and initial biological responses.
- Phase 2
Involves larger groups, sometimes hundreds of people, to further evaluate safety, refine dose and schedule, and gather early signs of effect.
- Phase 3
Large trials, often with thousands of participants at many sites, test whether the intervention works as intended and identify less common side effects. Results support regulatory decisions.
- Phase 4
After approval, studies and surveillance continue to monitor long-term safety and effectiveness in the broader population.
Some programs combine phases (for example, Phase 1/2 or Phase 2b) to answer questions more efficiently. Many candidates never progress beyond early phases, because they prove unsafe, ineffective or less promising than alternatives.
Study Design and Research Questions
Every trial starts with a precise research question and a defined primary endpoint, the main outcome used to judge success. Common design features include:
- Randomization: participants are assigned to groups by chance, so that the groups are similar except for the intervention being tested.
- Control groups: a comparison group receives a placebo, an existing standard intervention or no intervention.
- Blinding: in single-blind studies participants do not know their group; in double-blind studies neither participants nor investigators know, reducing bias.
- Pre-registration: describing the trial and its planned analyses in a public registry before results are known.
- RCT
- Randomized controlled trial
- A study in which participants are randomly assigned to an intervention or a control group. RCTs are considered the strongest design for testing whether an intervention causes an effect.
Informed Consent
Informed consent is a process, not just a signature. Before joining, a prospective participant should receive clear information about the study’s purpose, procedures, duration, foreseeable risks and discomforts, possible benefits, alternatives, how their information will be protected, and whom to contact with questions. They should have time to consider, ask questions and discuss with others.
Consent must be voluntary and free from coercion or undue influence. The process continues throughout the study: participants should be told about new information that might affect their willingness to stay. More on this appears in Research Ethics.
Participant Rights
- To receive understandable information about the study before deciding.
- To ask questions at any time and receive honest answers.
- To decline participation without affecting their usual medical care.
- To withdraw at any time without penalty.
- To have personal information kept confidential, within limits explained in advance.
- To be informed of new findings that may affect their decision to continue.
- To contact an ethics committee about concerns regarding their rights.
Clinical Trial Safety Monitoring
Safety oversight operates at several levels. Investigators record and report adverse events. Sponsors review safety data across sites. An independent ethics committee—in the United States, an Institutional Review Board (IRB)—approves the protocol and monitors the study. Many larger trials also have an independent Data and Safety Monitoring Board (DSMB), which reviews unblinded data at planned intervals and can recommend modifying, pausing or stopping the trial for safety, clear benefit or futility. Regulators may also inspect trial conduct.
Data Collection and Study Outcomes
Trials collect data through clinical examinations, laboratory tests, questionnaires and diaries. Data are checked for quality and analyzed according to the pre-specified plan. Results are typically described in terms of the primary endpoint, secondary endpoints and safety outcomes. Reputable trials report results whether they are positive, negative or inconclusive; many jurisdictions, including the United States, require results for certain trials to be posted in public registries.
Understanding Research Limitations
Even a well-run trial has limits. Participants may not represent everyone who will eventually use the intervention. Follow-up may be too short to detect long-term effects. Rare side effects may require far larger populations to identify. A result can be statistically significant yet small in practical terms, or a real effect can be missed because a trial was too small. Our Public Health Literacy guide explains these concepts further.
Ethical Participation
Ethical research depends on fairness in who is invited, honesty in how studies are described, respect for participants’ decisions, and a commitment to share results with participants and communities. Partnership with affected communities, described on our Community Engagement page, helps make trials more relevant and trustworthy.
Frequently Asked Questions
Is joining a clinical trial the same as getting treatment?
No. A clinical trial is research designed to answer a scientific question. An investigational product has not yet been proven safe and effective for its intended use, and participants may receive a placebo or a comparison intervention instead. Established treatment, by contrast, is care that has already been shown to work and is recommended by clinical guidelines.
Can I leave a clinical trial after I have started?
Yes. Participation is voluntary, and participants can withdraw at any time without penalty or loss of benefits to which they are otherwise entitled. The research team may ask about safety follow-up, but cannot require a participant to stay.
Will I be paid for taking part?
Some studies compensate participants for time, travel or inconvenience. Ethics committees review payment to make sure it is not so large that it could pressure people into accepting risks they would otherwise refuse.
Why do some trials use a placebo?
A placebo helps researchers separate the real effects of an intervention from changes that would have happened anyway, or from expectations. Ethical guidance generally restricts placebo use when an effective proven intervention exists and withholding it would expose participants to serious harm.
Does this website list trials I can join?
No. THE VARG is an educational website, not a trial registry or recruitment service. Public registries maintained by national health authorities and conversations with qualified clinicians are appropriate places to look.